DekaBank Deutsche Girozentrale decreased its stake in shares of Danaher Co. (NYSE:DHR) by 13.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 482,180 shares of the conglomerate’s stock after selling 76,206 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Danaher were worth $68,743,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Northern Trust Corp grew its position in Danaher by 0.4% in the 1st quarter. Northern Trust Corp now owns 8,887,690 shares of the conglomerate’s stock valued at $1,173,352,000 after purchasing an additional 34,065 shares during the period. Geode Capital Management LLC grew its position in Danaher by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 7,527,142 shares of the conglomerate’s stock valued at $774,743,000 after purchasing an additional 583,194 shares during the period. Findlay Park Partners LLP grew its position in Danaher by 0.9% in the 1st quarter. Findlay Park Partners LLP now owns 4,635,000 shares of the conglomerate’s stock valued at $611,913,000 after purchasing an additional 40,000 shares during the period. Jennison Associates LLC acquired a new stake in Danaher in the 1st quarter valued at $489,930,000. Finally, American Century Companies Inc. grew its position in Danaher by 3.7% in the 1st quarter. American Century Companies Inc. now owns 3,700,569 shares of the conglomerate’s stock valued at $488,549,000 after purchasing an additional 133,300 shares during the period. 79.35% of the stock is owned by institutional investors.
Shares of Danaher stock opened at $140.54 on Wednesday. Danaher Co. has a 52-week low of $94.59 and a 52-week high of $145.50. The firm has a 50-day moving average price of $141.56. The company has a market cap of $100.65 billion, a PE ratio of 31.09, a P/E/G ratio of 2.53 and a beta of 0.94. The company has a quick ratio of 1.91, a current ratio of 2.32 and a debt-to-equity ratio of 0.33.
Several equities analysts have weighed in on the company. Wolfe Research assumed coverage on Danaher in a research note on Thursday, May 30th. They set an “outperform” rating on the stock. Argus raised their price objective on Danaher to $165.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Zacks Investment Research upgraded Danaher from a “sell” rating to a “hold” rating in a research note on Monday, May 6th. Needham & Company LLC restated a “buy” rating and set a $155.00 price objective (up from $142.00) on shares of Danaher in a research note on Friday, July 19th. Finally, Royal Bank of Canada set a $134.00 price objective on Danaher and gave the company a “hold” rating in a research note on Friday, July 19th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $143.54.
In other Danaher news, insider Brian W. Ellis sold 1,010 shares of Danaher stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $144.04, for a total transaction of $145,480.40. Following the completion of the transaction, the insider now owns 20,889 shares of the company’s stock, valued at approximately $3,008,851.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Robert S. Lutz sold 14,668 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $143.28, for a total value of $2,101,631.04. Following the transaction, the chief accounting officer now directly owns 21,054 shares of the company’s stock, valued at approximately $3,016,617.12. The disclosure for this sale can be found here. Insiders sold a total of 392,121 shares of company stock worth $53,603,339 over the last 90 days. 11.40% of the stock is currently owned by company insiders.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: What can cause a stock to outperform?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.